Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Microb Pathog ; 193: 106789, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38972365

ABSTRACT

Urinary tract infections (UTIs) by Uropathogenic Escherichia coli (UPEC) are a significant health concern, especially due to the increasing prevalence of antibiotic resistance. This study focuses on isolating and characterizing bacteriophages specific to UPEC strains isolated from UTI samples. The isolated phages were assessed for their ability to target and lyse UPEC in vitro, focusing on their efficacy in disrupting biofilms, a key virulence factor contributing to UTI recurrence and antibiotic resistance. The morphological structure observed by TEM belongs to Myoviridae, the phage exhibited icosahedral symmetry with a long non-constricting tail, the approximate measurement of the phage head was 39 nm in diameter, and the phage tail was 105.317 nm in length. One-step growth experiments showed that the latent period was approximately 20 min, followed by a rise period of 40 min, and a growth plateau was reached within 20 min and the burst size observed was 26 phages/infected bacterial cells. These phages were capable of killing cells within the biofilms, leading to a reduction in living cell counts after a single treatment. This study highlights the potential of phages to play a significant role in disrupting, inactivating, and destroying Uropathogenic Escherichia coli (UPEC) biofilms. Such findings could be instrumental in developing treatment strategies that complement antibiotics and disinfectants. The phage-antibiotic synergistic activity was compared to have the possibility to facilitate the advancement of focused and enduring alternatives to traditional antibiotic therapies for UTIs.


Subject(s)
Anti-Bacterial Agents , Bacteriophages , Biofilms , Escherichia coli Infections , Urinary Tract Infections , Uropathogenic Escherichia coli , Biofilms/drug effects , Biofilms/growth & development , Urinary Tract Infections/microbiology , Uropathogenic Escherichia coli/drug effects , Uropathogenic Escherichia coli/virology , Anti-Bacterial Agents/pharmacology , Humans , Escherichia coli Infections/microbiology , Bacteriophages/isolation & purification , Bacteriophages/physiology , Phage Therapy , Myoviridae/isolation & purification , Myoviridae/physiology , Drug Synergism , Microbial Sensitivity Tests
SELECTION OF CITATIONS
SEARCH DETAIL